

Ratika Parkash

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1259566/publications.pdf>

Version: 2024-02-01

97
papers

3,628
citations

236833

25
h-index

138417

58
g-index

99
all docs

99
docs citations

99
times ranked

3814
citing authors

#	ARTICLE	IF	CITATIONS
1	Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. <i>New England Journal of Medicine</i> , 2016, 375, 111-121.	13.9	616
2	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1847-1948.	0.8	313
3	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1170-1185.	0.8	243
4	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1371-1392.	0.8	195
5	Complications associated with defibrillation threshold testing: The Canadian experience. <i>Heart Rhythm</i> , 2008, 5, 387-390.	0.3	159
6	Approach to the Catheter Ablation Technique of Paroxysmal and Persistent Atrial Fibrillation: A Meta-Analysis of the Randomized Controlled Trials. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 729-738.	0.8	118
7	Fludrocortisone for the Prevention of Vasovagal Syncope. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1-9.	1.2	116
8	Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. <i>Cmaj</i> , 2011, 183, 421-429.	0.9	112
9	Standardized Approaches to the Investigation of Syncope: Canadian Cardiovascular Society Position Paper. <i>Canadian Journal of Cardiology</i> , 2011, 27, 246-253.	0.8	111
10	Clinical Predictors of Fidelis Lead Failure. <i>Circulation</i> , 2012, 125, 1217-1225.	1.6	103
11	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2845-2854.	1.2	94
12	Complications Associated With Revision of Sprint Fidelis Leads. <i>Circulation</i> , 2010, 121, 2384-2387.	1.6	88
13	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 174-188.	0.8	84
14	An Integrated Management Approach to Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	76
15	Predicting early mortality after implantable defibrillator implantation: A clinical risk score for optimal patient selection. <i>American Heart Journal</i> , 2006, 151, 397-403.	1.2	73
16	Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation. <i>Circulation</i> , 2017, 135, 1788-1798.	1.6	66
17	Atrial fibrillation in heart failure: High mortality risk even if ventricular function is preserved. <i>American Heart Journal</i> , 2005, 150, 701-706.	1.2	55
18	Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. <i>Circulation</i> , 2022, 145, 1693-1704.	1.6	54

#	ARTICLE	IF	CITATIONS
19	Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection. <i>Canadian Journal of Cardiology</i> , 2013, 29, 182-195.	0.8	53
20	Failure rate of the Riata lead under advisory: A report from the CHRS Device Committee. <i>Heart Rhythm</i> , 2013, 10, 692-695.	0.3	44
21	Persistent atrial fibrillation: current approach and controversies. <i>Current Opinion in Cardiology</i> , 2010, 25, 1-7.	0.8	42
22	Intramural Ventricular Recording and Pacing in Patients With Refractory Ventricular Tachycardia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1181-1188.	2.1	32
23	Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	31
24	Use of Primary Prevention Implantable Cardioverter-Defibrillators in a Population-Based Cohort Is Associated With a Significant Survival Benefit. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 706-713.	2.1	29
25	Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 660-668.	1.3	27
26	Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool. <i>American Heart Journal</i> , 2020, 224, 35-46.	1.2	27
27	The impact of warfarin use on clinical outcomes in atrial fibrillation: A population-based study. <i>Canadian Journal of Cardiology</i> , 2007, 23, 457-461.	0.8	26
28	2021 CAEP Acute Atrial Fibrillation/Flutter Best Practices Checklist. <i>Canadian Journal of Emergency Medicine</i> , 2021, 23, 604-610.	0.5	25
29	Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study. <i>American Heart Journal</i> , 2018, 201, 149-157.	1.2	23
30	Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1346-1360.	0.8	22
31	Prescribing of oral anticoagulants in the emergency department and subsequent long-term use by older adults with atrial fibrillation. <i>Cmaj</i> , 2019, 191, E1345-E1354.	0.9	22
32	Sprint Fidelis Lead Fractures in Patients With Cardiac Resynchronization Therapy Devices. <i>Circulation</i> , 2012, 126, 2928-2934.	1.6	20
33	A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. <i>American Heart Journal</i> , 2021, 234, 90-100.	1.2	20
34	Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005663.	2.1	18
35	Use of Administrative Data to Monitor Cardiac Implantable Electronic Device Complications. <i>Canadian Journal of Cardiology</i> , 2019, 35, 100-103.	0.8	18
36	Canadian Registry of Implantable Electronic Device Outcomes. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	17

#	ARTICLE	IF	CITATIONS
37	The Effect of Shock Burden on Heart Failure and Mortality. <i>CJC Open</i> , 2019, 1, 161-167.	0.7	17
38	Sex Differences in Vasovagal Syncope: A Post Hoc Analysis of the Prevention of Syncope Trials (POST) I and II. <i>Canadian Journal of Cardiology</i> , 2020, 36, 79-83.	0.8	17
39	Remote Monitoring of Cardiovascular Implantable Electronic Devices in Canada: Survey of Patients and Device Health Care Professionals. <i>CJC Open</i> , 2021, 3, 391-399.	0.7	17
40	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. <i>Europace</i> , 2017, 19, 1630-1636.	0.7	16
41	Cardiac Arrhythmias and Pregnancy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 63.	0.4	16
42	Effect of coronary revascularization on long-term clinical outcomes in patients with ischemic cardiomyopathy and recurrent ventricular arrhythmia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 775-779.	0.5	16
43	Insight into the mechanism of failure of the Riata lead under advisory. <i>Heart Rhythm</i> , 2015, 12, 574-579.	0.3	15
44	The Canadian Community Utilization of Stroke Prevention Study in Atrial Fibrillation in the Emergency Department (C-CUSP ED). <i>Annals of Emergency Medicine</i> , 2019, 73, 382-392.	0.3	15
45	Prospective Assessment of an Automated Intraprocedural 12-Lead ECG-Based System for Localization of Early Left Ventricular Activation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008262.	2.1	15
46	Mortality Risk Increases With Clustered Ventricular Arrhythmias in Patients With Implantable Cardioverter-Defibrillators. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 327-337.	1.3	15
47	Pulmonary Vein Stenosis After Atrial Fibrillation Ablation: Insights From the ADVICE Trial. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1965-1974.	0.8	14
48	Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study. <i>Cmaj</i> , 2004, 171, 1053-1056.	0.9	13
49	Ventricular Tachycardia Ablation versus Antiarrhythmic-Drug Escalation. <i>New England Journal of Medicine</i> , 2016, 375, 1498-1500.	13.9	13
50	Primary Prevention of Sudden Cardiac Death With Device Therapy in Urban and Rural Populations. <i>Canadian Journal of Cardiology</i> , 2017, 33, 437-442.	0.8	13
51	Role of contact force in ischemic scar-related ventricular tachycardia ablation; optimal force required and impact of left ventricular access route. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 53, 323-331.	0.6	13
52	Safe Cardioversion for Patients With Acute-Onset Atrial Fibrillation and Flutter: Practical Concerns and Considerations. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1296-1300.	0.8	13
53	Benefit of Implantable Cardioverter-Defibrillator Generator Replacement in a Primary Prevention Population-Based Cohort. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1180-1189.	1.3	12
54	Cardiac Resynchronization in Women. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 1036-1044.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Integrated Management Approach to Atrial Fibrillation Care: A Cost Utility Analysis. Canadian Journal of Cardiology, 2019, 35, 1142-1148.	0.8	12
56	The Canadian Cardiovascular Society 2018 guideline update for atrial fibrillation – A different perspective. Canadian Journal of Emergency Medicine, 2019, 21, 572-575.	0.5	11
57	The Effect of Cardiac Rehabilitation and a Specialized Clinic on Outcomes of Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2019, 35, 382-388.	0.8	11
58	Predictors of perforation during lead extraction: Results of the Canadian Lead ExtrAction Risk (CLEAR) study. Heart Rhythm, 2022, 19, 1097-1103.	0.3	10
59	Anticoagulation and population risk of stroke and death in incident atrial fibrillation: a population-based cohort study. CMAJ Open, 2016, 4, E1-E6.	1.1	9
60	Adverse Events Associated With Electrical Cardioversion in Patients With Acute Atrial Fibrillation and Atrial Flutter. Canadian Journal of Cardiology, 2021, 37, 1775-1782.	0.8	9
61	Management of Implantable Cardioverter Defibrillator Recipients: Care Beyond Guidelines. Canadian Journal of Cardiology, 2017, 33, 977-990.	0.8	8
62	The influence of sex and age on ventricular arrhythmia in a population-based registry. International Journal of Cardiology, 2017, 244, 169-174.	0.8	8
63	Remote-only monitoring for patients with cardiac implantable electronic devices: a before-and-after pilot study. CMAJ Open, 2021, 9, E53-E61.	1.1	7
64	Ventricular tachycardia ablation in arrhythmogenic right ventricular cardiomyopathy patients with TMEM43 gene mutations. Journal of Cardiovascular Electrophysiology, 2018, 29, 90-97.	0.8	6
65	Automated intraprocedural localization of origin of ventricular activation using patient-specific computed tomographic imaging. Heart Rhythm, 2020, 17, 567-575.	0.3	6
66	Prospective Study of Skipping Meals to Lose Weight as a Predictor of Incident Type 2 Diabetes With Potential Modification by Cardiometabolic Risk Factors: The Canadian 1995 Nova Scotia Health Survey. Canadian Journal of Diabetes, 2021, 45, 306-312.	0.4	6
67	Body-surface potential mapping to aid ablation of scar-related ventricular tachycardia. Journal of Electrocardiology, 2006, 39, S87-S95.	0.4	5
68	RAFF-3 Trial: A Stepped-Wedge Cluster Randomised Trial to Improve Care of Acute Atrial Fibrillation and Flutter in the Emergency Department. Canadian Journal of Cardiology, 2021, 37, 1569-1577.	0.8	5
69	Polymorphic ventricular tachycardia due to change in pacemaker programming. HeartRhythm Case Reports, 2017, 3, 243-247.	0.2	4
70	Canadian Registry of Implantable Electronic Device Outcomes: Longer-term follow-up of the Riata lead under advisory. Heart Rhythm, 2018, 15, 524-529.	0.3	4
71	Patient-Reported Outcomes and Patient-Reported Experience of Patients With Atrial Fibrillation in the IMPACT-AF Clinical Trial. Journal of the American Heart Association, 2021, 10, e019783.	1.6	4
72	Predicting Sudden Cardiac Death After Myocardial Infarction. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009422.	2.1	4

#	ARTICLE	IF	CITATIONS
73	Ventricular tachycardia characteristics and outcomes with catheter ablation vs. antiarrhythmic therapy: insights from the VANISH trial. <i>Europace</i> , 2022, 24, 1112-1118.	0.7	4
74	Rhythm Control Vs Rate Control in a Contemporary Ambulatory Atrial Fibrillation Cohort: Post Hoc Analysis of the IMPACT-AF Trial. <i>CJC Open</i> , 2022, 4, 551-557.	0.7	4
75	Virtual follow-up and care for patients with cardiac electronic implantable devices: protocol for a systematic review. <i>Systematic Reviews</i> , 2020, 9, 153.	2.5	3
76	The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 445.	0.7	3
77	Canadian Heart Rhythm Society Task Force Report on Physician Training and Maintenance of Competency for Cardiovascular Implantable Electronic Device Therapies: Executive Summary. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1857-1860.	0.8	3
78	Triggers, Substrate, and Hypertension in Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2015, 1, 174-176.	1.3	2
79	Differentiating Ventricular From Supraventricular Arrhythmias Using the Postpacing Interval After Failed Antitachycardia Pacing. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005921.	2.1	2
80	Canadian Registry of Implantable Electronic Device Outcomes: Surveillance of High-Voltage Leads. <i>Canadian Journal of Cardiology</i> , 2018, 34, 808-811.	0.8	2
81	The effect of revascularization on mortality and risk of ventricular arrhythmia in patients with ischemic cardiomyopathy. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 455.	0.7	2
82	Patient and healthcare provider reported barriers and enablers to virtual or remote-only follow-up models for cardiovascular implantable electronic devices: protocol for a qualitative framework synthesis. <i>Systematic Reviews</i> , 2020, 9, 151.	2.5	2
83	Canadian Registry of Electronic Device Outcomes: remote monitoring outcomes in the Abbott battery performance alert—a multicentre cohort. <i>Europace</i> , 2021, 23, 1319-1323.	0.7	2
84	Lessons learned from Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): a pragmatic clinical trial of computerized decision support in primary care. <i>Trials</i> , 2021, 22, 531.	0.7	2
85	Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study. <i>JAMA Network Open</i> , 2021, 4, e2136830.	2.8	2
86	Cardiovascular Outcomes in Nova Scotia During the Early Phase of the COVID-19 Pandemic. <i>CJC Open</i> , 2022, 4, 324-336.	0.7	2
87	Early Catheter Ablation for Unstable Ventricular Tachycardia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	1
88	Implantable Cardioverter-Defibrillators in Sudden Cardiac Death Survivors: Are We Doing All We Can?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1215-1216.	0.8	1
89	Lead-lead interaction: Interaction with an abandoned implantable cardiac defibrillator externalized lead. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1040-1041.	0.8	1
90	Left Atrial Function and Sudden Cardiac Death. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1091-1093.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Canadian Registry of Electronic Device Outcomes (CREDO): The Abbott ICD Premature Battery Depletion Advisory, a Multicentre Cohort Study. CJC Open, 2021, 3, 48-53.	0.7	1
92	Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis. Journal of Thrombosis and Thrombolysis, 2022, 53, 74-82.	1.0	1
93	Comparative effectiveness of ventricular tachycardia ablation vs. escalated antiarrhythmic drug therapy by location of myocardial infarction: a sub-study of the VANISH trial. Europace, 2022, 24, 948-958.	0.7	1
94	Narrow, Intermediate, and Wide Complex Tachycardia: What Is the Mechanism?. Journal of Cardiovascular Electrophysiology, 2016, 27, 494-496.	0.8	0
95	Response by Parkash et al to Letters Regarding Article, "Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control])". Circulation, 2017, 136, 1271-1272.	1.6	0
96	An Evaluation of Device-Measured Physical Activity Levels of Patients With Nonpermanent Atrial Fibrillation. Journal of Cardiopulmonary Rehabilitation and Prevention, 2021, 41, 440-442.	1.2	0
97	Abstract 14586: Variability in Indicated Left Ventricular Function Reassessment After Mi: The Acute Myocardial Infarction Quality Assurance (AMIQA) Canada Multicenter Prospective Study. Circulation, 2020, 142, .	1.6	0